DK1559715T3 - N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form - Google Patents

N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form

Info

Publication number
DK1559715T3
DK1559715T3 DK03756734T DK03756734T DK1559715T3 DK 1559715 T3 DK1559715 T3 DK 1559715T3 DK 03756734 T DK03756734 T DK 03756734T DK 03756734 T DK03756734 T DK 03756734T DK 1559715 T3 DK1559715 T3 DK 1559715T3
Authority
DK
Denmark
Prior art keywords
quinolyl
isoxazolyl
dimethoxy
chloro
oxy
Prior art date
Application number
DK03756734T
Other languages
Danish (da)
English (en)
Inventor
Naoki Matsunaga
Satoshi Yoshida
Ayako Yoshino
Tatsuo Nakajima
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of DK1559715T3 publication Critical patent/DK1559715T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03756734T 2002-10-21 2003-10-21 N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form DK1559715T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002306101 2002-10-21
PCT/JP2003/013439 WO2004035572A1 (ja) 2002-10-21 2003-10-21 Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形

Publications (1)

Publication Number Publication Date
DK1559715T3 true DK1559715T3 (da) 2007-12-27

Family

ID=32105192

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03756734T DK1559715T3 (da) 2002-10-21 2003-10-21 N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form

Country Status (10)

Country Link
US (1) US7166722B2 (de)
EP (1) EP1559715B1 (de)
JP (1) JP3763414B2 (de)
AT (1) ATE374199T1 (de)
AU (1) AU2003301430A1 (de)
DE (1) DE60316590T2 (de)
DK (1) DK1559715T3 (de)
ES (1) ES2294317T3 (de)
PT (1) PT1559715E (de)
WO (1) WO2004035572A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253051T1 (de) * 1999-01-22 2003-11-15 Kirin Brewery Chinolinderivate und chinazolinderivate
EP2280003B1 (de) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Verfahren zur Herstellung von Rezeptorkinase-Modulatoren
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
CA2581835C (en) * 2004-09-29 2012-12-18 Bayer Healthcare Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US9037466B2 (en) * 2006-03-09 2015-05-19 Nuance Communications, Inc. Email administration for rendering email on a digital audio player
EP2387563B2 (de) 2009-01-16 2022-04-27 Exelixis, Inc. Malatsalz von n-(4-{[6,7-bis(methyloxy)chinolin-4-yl]-oxy}phenyl-n'-(4-fluorphenyl)cyclo-propan-1,1-dicarbonsäureamid und kristalline formen davon zur behandlung von krebs
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
SI2621481T2 (sl) 2010-09-27 2023-02-28 Exelixis, Inc., Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz
KR20210010671A (ko) * 2011-02-10 2021-01-27 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
CN102532116B (zh) * 2011-08-09 2015-01-21 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN104072492A (zh) * 2013-11-27 2014-10-01 苏州摩尔医药有限公司 一种抗肿瘤靶向治疗药物Tivozanib的合成方法
KR102340311B1 (ko) * 2016-09-13 2021-12-20 쿄와 기린 가부시키가이샤 의약 조성물
CA3118690A1 (en) 2018-11-05 2020-05-14 Aveo Pharmaceuticals, Inc. Use of tivozanib to treat subjects with refractory cancer
WO2023096651A1 (en) 2021-11-26 2023-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating bile duct cancers with tivozanib
CN114213404A (zh) * 2021-12-27 2022-03-22 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
WO2024095127A1 (en) 2022-10-31 2024-05-10 Pliva Hrvatska D.O.O. Solid state forms of tivozanib and process for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505844A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
AU2223201A (en) * 1999-12-24 2001-07-09 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
RU2283841C2 (ru) * 2001-04-27 2006-09-20 Кирин Бир Кабусики Кайся Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration

Also Published As

Publication number Publication date
JPWO2004035572A1 (ja) 2006-02-16
PT1559715E (pt) 2007-10-24
US20060052415A1 (en) 2006-03-09
US7166722B2 (en) 2007-01-23
JP3763414B2 (ja) 2006-04-05
EP1559715B1 (de) 2007-09-26
WO2004035572A1 (ja) 2004-04-29
ATE374199T1 (de) 2007-10-15
EP1559715A1 (de) 2005-08-03
DE60316590T2 (de) 2008-06-19
ES2294317T3 (es) 2008-04-01
AU2003301430A1 (en) 2004-05-04
DE60316590D1 (en) 2007-11-08
EP1559715A4 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
DK1559715T3 (da) N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form
RU2207341C2 (ru) Новые циклические соединения диамина, содержащие их лекарственные средства и способы лечения
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
NZ528851A (en) N-aroyl cyclic amines
RU99128053A (ru) Новые циклические соединения диамина и содержащие их лекарственные средства
BR9812046A (pt) Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto
NO912410D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklen-derivater.
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
BRPI0412219B8 (pt) compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
NO980848D0 (no) Piperazinoderivater som neurokininantagonister
IT1226727B (it) Farmaci precursori della dopamina.
NO20040881L (no) Orale antidiabetes midler.
BR0113590A (pt) 7-oxo-piridopirimidinas
DK1465625T3 (da) Opløste topoisomerase-gifte
DK1251846T3 (da) C4-Carbonattaxaner
RU2008127260A (ru) Производные хиназолинона в качестве антагонистов ваниллоидов
DK0397365T3 (da) Arylthiazolylimidazoler som 5HT3-antagonister
ES2089974B1 (es) Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
ATE137223T1 (de) Leukotrien-b4-antagonisten
DK336387D0 (da) 4-(aroylamino)-piperidinbutanamidderivater
FI964303A0 (fi) Keuhkosydänvian hoitamiseen tarkoitettu aine